Shares of Theravance Biopharma (TBPH -1.02%) were mauled in September, along with most other biotech stocks in general.
Does the big sell-off represent a buying opportunity? Read the presentation below to find out.
S&P 500
5,911.69
-0.0%
-$0.48
DJI
42,270.07
+0.1%
+$54.34
NASDAQ
19,113.77
-0.3%
-$62.11
Bitcoin
103,775.00
-1.8%
-1,939.33
AAPL
$201.47
+0.8%
+$1.52
AMZN
$205.07
-0.3%
-$0.63
GOOG
$173.06
+0.1%
+$0.10
META
$648.23
+0.5%
+$3.18
MSFT
$460.71
+0.4%
+$2.03
NVDA
$135.22
-2.9%
-$3.97
TSLA
$346.82
-3.2%
-$11.61
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Theravance Biopharma Inc. Fell 20% in September
By Brian Feroldi
–
Oct 24, 2015 at 8:33AM
NASDAQ: TBPH
Theravance Biopharma
Market Cap
$458M
Today's Change
(-1.02%) -$0.10
Current Price
$9.21
Price as of May 30, 2025, 3:56 p.m. ET
Despite releasing some good news, a rough month for biotech stocks in general crushed the company's stock.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Theravance Biopharma
TBPH
$9.21
(-1.02%)
$0.10
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Theravance Biopharma, inc (TBPH) Q3 2021 Earnings Call Transcript
Why Theravance Biopharma Stock Dived 16% Today
Here's Why Theravance Biopharma Stock Is Tanking Today
Theravance Biopharma, inc (TBPH) Q2 2021 Earnings Call Transcript
Theravance Biopharma Inc (TBPH) Q1 2021 Earnings Call Transcript
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.